Spravato (Esketamine) Treatment
A breakthrough FDA-approved nasal spray for adults with treatment-resistant depression — delivering relief in days, not weeks.
FDA-Approved
Since 2019 for TRD
Rapid Relief
Often within days
2-Hour
Monitored session
New Mechanism
NMDA receptor pathway
A New Option When Antidepressants Haven't Worked
Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression (TRD) or major depressive disorder (MDD) with active suicidal ideation or behavior. It represents a significant breakthrough in psychiatric treatment — the first truly new mechanism of action for depression in decades.
Unlike traditional antidepressants that target serotonin, norepinephrine, or dopamine, Spravato works on the NMDA receptor system in the brain. This different mechanism allows many patients to experience meaningful symptom relief within hours to days — rather than the 4–8 weeks typical of oral antidepressants.
Spravato is administered in our certified healthcare setting under direct medical supervision. Patients self-administer the nasal spray and are monitored for at least 2 hours after each session. It is used in conjunction with an oral antidepressant as part of a comprehensive treatment plan.
How Spravato Differs from Antidepressants
- Targets NMDA receptors, not serotonin or dopamine
- Relief often within hours to days vs. 4–8 weeks
- FDA-approved specifically for treatment-resistant cases
- Administered in-office under medical supervision
- Used alongside an oral antidepressant
Important Safety Note
You cannot drive on the day of your Spravato treatment. Please arrange transportation. You will be monitored for at least 2 hours after each session.
FDA-Approved Indications
Treatment-Resistant Depression (TRD)
For adults who have tried at least two oral antidepressants at adequate doses and durations without sufficient relief.
MDD with Suicidal Ideation
FDA-approved for adults with major depressive disorder with active suicidal ideation or behavior requiring rapid symptom reduction.
Rapid-Onset Depression Relief
For patients who need faster relief than traditional antidepressants can provide — particularly during acute depressive episodes.
The Spravato Treatment Process
A structured, supervised process designed for your safety and maximum therapeutic benefit.
Consultation & Evaluation
Meet with Amy Burchett, PMHNP to determine if Spravato is appropriate for your diagnosis and treatment history.
REMS Enrollment
Spravato is dispensed through the FDA's REMS program. We handle the enrollment process and coordinate with your pharmacy.
In-Office Treatment Sessions
You self-administer the nasal spray in our certified setting. Sessions are twice weekly for 4 weeks, then weekly, then every 1–2 weeks.
2-Hour Monitoring
You are monitored for at least 2 hours after each dose for potential side effects including dissociation and sedation before being cleared to leave.
Could Spravato Be Right for You?
If you've tried antidepressants without adequate relief, Spravato may offer the breakthrough you've been looking for. Schedule a consultation to find out.
Spravato: Frequently Asked Questions
What is Spravato (esketamine)?
Spravato is an FDA-approved nasal spray containing esketamine, a derivative of ketamine. It works on NMDA receptors in the brain — a different pathway than traditional antidepressants — and is approved for treatment-resistant depression and MDD with suicidal ideation.
How is Spravato different from ketamine infusions?
Spravato is FDA-approved specifically for depression and is administered as a nasal spray in a certified healthcare setting. Ketamine infusions are typically IV-administered and used off-label. Both target NMDA receptors, but Spravato has a standardized, FDA-regulated protocol.
How quickly does Spravato work?
Many patients begin to notice symptom improvement within hours to days of their first treatment. The full therapeutic benefit typically develops over the first 4 weeks of twice-weekly treatment.
Can I drive after a Spravato session?
No. Due to the risk of sedation and dissociation, you cannot drive or operate heavy machinery on the day of your Spravato treatment. You must arrange for someone to drive you home after each session.
Is Spravato covered by insurance?
Many insurance plans cover Spravato for FDA-approved indications. As an out-of-network provider, we recommend verifying your benefits. We can provide documentation to support your insurance claim.
What are the side effects of Spravato?
Common side effects include dissociation, dizziness, nausea, sedation, and increased blood pressure during the session. These typically resolve within 2 hours of administration, which is why on-site monitoring is required.
Explore Related Services
NeuroStar TMS Therapy
FDA-cleared, non-invasive magnetic stimulation for treatment-resistant depression.
Learn moreTelehealth Psychiatry
Comprehensive psychiatric evaluation and medication management via secure video.
Learn moreMedication Management
Ongoing psychiatric medication oversight tailored to your unique needs.
Learn moreTake the Next Step Toward Relief
If antidepressants haven't worked, Spravato may be the answer. Schedule a consultation with Amy Burchett, PMHNP today.
Powered by AdvancedMD — HIPAA-compliant secure patient portal